



What is pA1c®?

Pediococcus acidilactici pA1c® is a probiotic for the long-term and sustained regulation of normal blood glucose levels supported by science, and therefore an outstanding active ingredient to maintain metabolic health.


Pediococcus acidilactici is a well-known bacterial species, used by humans to ferment foods for centuries. It is included in the Qualified Presumption of Safety (QPS) list of the European Food Safety Authority (EFSA). pA1c®'s safety has been demonstrated *in vivo* and is Generally Recognized as Safe (GRAS) in the USA.

The science behind pA1c®

Research shows that pA1c® is able to:


PREVENT TYPE-2 DIABETES

Mice supplemented with pA1c® were less likely to develop type-2 diabetes when fed hypercaloric diet by regulating blood glucose levels^[1-3]. Blood glucose regulation has been also shown in obese mice^[4].




IMPROVE DIABETES TREATMENT:

Combination of pA1c® with metformin is safe and long-term glycemic regulation is more effective. In this study, pA1c® alone outperformed metformin in lowering blood glucose levels in diabetic mice^[1,2].




PREVENT GESTATIONAL DIABETES:

Pregnant mice supplemented with pA1c® were less likely to develop gestational diabetes^[3]. Supplementation with pA1c® reduced fasting blood sugar levels during pregnancy, keeping its values similar to those found in non-diabetic pregnant mice.



How does pA1c[®] work?

Studies show that pA1c[®] regulates blood sugar levels via multiple synergistic mechanisms acting together, from microbiome modulation to physiological changes^[1,2,4]:



About Genbioma

Genbioma is a biotechnology company which spun-off from the Public University of Navarra (UPNA), that is devoted to the development and commercialization of next-generation probiotic strains, postbiotic and synbiotic ingredients, with a focus on applications on metabolic health. Genbioma's innovative capacity has been awarded with the select seal of Innovative SME issued by the Spanish Ministry of Science and Innovation.

The company was founded in 2019 and is backed by leading partners from different sectors:



References

- [1] Cabello-Olmo, M. *et al.* "Pediococcus acidilactici pA1c[®] Improves the Beneficial Effects of Metformin Treatment in Type 2 Diabetes by Controlling Glycaemia and Modulating Intestinal Microbiota". *Parmaceutics*, 2023, 15, 1203, <https://doi.org/10.3390/pharmaceutics15041203>
- [2] Cabello-Olmo, M. *et al.* "Antidiabetic effects of *Pediococcus acidilactici* pA1c on HFD _ induced mice", *Nutrients*, 2022, 46, 1–21, <https://doi.org/10.3390/nu14030692>
- [3] Data on file
- [4] Yavorov-Dayliev *et al.* "Glucose-lowering effects of a synbiotic combination containing *Pediococcus acidilactici* in *C. elegans* and mice". *Diabetologia*, 2023, 66:2117–2138 <https://doi.org/10.1007/s00125-023-05981-w>

